{"nctId":"NCT01000662","briefTitle":"Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor","startDateStruct":{"date":"2009-03"},"conditions":["Breast Cancer"],"count":412,"armGroups":[{"label":"ARM 1 daily boost","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: Daily Radiation Therapy"]},{"label":"ARM 2 weekly boost","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: Weekly Radiation Therapy"]}],"interventions":[{"name":"Daily Radiation Therapy","otherNames":[]},{"name":"Weekly Radiation Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pre or post-menopausal women with stage 0,I, and II breast cancer\n* Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm\n* Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (DCIS and Tumors \\<5mm do not require nodal assessment)\n* At least 2 weeks from last chemotherapy\n* Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Previous radiation therapy to the ipsilateral breast\n* More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary radiation\n* Active connective tissue disorders, such as lupus or scleroderma\n* Prior or concurrent malignancy other than basal or squamous cell skin cancer or carcinoma in-situ of the cervix, unless disease-free \\>3 years\n* Pregnant or lactating women","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Acute Radiation Toxicities Recorded According to Radiation Therapy Oncology Group (RTOG)","description":"Number of patients with a grade 2 or greater toxicity after 3 weeks of whole breast IMRT with a once/week boost compared to those patients treated with a daily boost: 0 - no symptoms, 5 - death directly related to radiation effects","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Score on Breast Cancer Treatment Outcomes Scale (BCTOS) at Baseline","description":"BCTOS is a validated questionnaire designed to measure breast esthetic and function after breast-conservations treatment. Patients rate the difference between their untreated and treated breast in 3 categories.\n\nThere are 4 score levels: 1 = \"No difference\"; 2 = \"Slight\"; 3 = \"Moderate\"; 4 = \"Large difference\". The total range is 3-12; the lower the score the lower the difference between the untreated and treated breast.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.89","spread":"2.72"},{"groupId":"OG001","value":"7.03","spread":"2.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.71","spread":"3.2"},{"groupId":"OG001","value":"9.9","spread":"3.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":"1.28"},{"groupId":"OG001","value":"3.87","spread":"1.47"}]}]}]},{"type":"SECONDARY","title":"Score on \"SF-36 v2 Vitality\" Scale","description":"SF-36 is an extensively used questionnaire designed to compare health status across various populations and is commonly used in cancer trials Our survey includes the portion of the SF-36 focused on the assessment of patient fatigue, or \"vitality,\" at various stages of treatment Example question: How much of the time during the past 4 weeks did you feel full of life? (Answer on scale 1 to 5). 1 = \"All of the time\"; 2 = \"Most of the time\"; 3 = \"Some of the time\"; 4 = \"A little of the time\"; 5 = \"None of the time\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":"0.91"},{"groupId":"OG001","value":"2.65","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.88"},{"groupId":"OG001","value":"3.3","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Average Score on Brief Pain Inventory (BPI) Scale","description":"The BPI is a self-administered assessment tool used in pain management.\n\nThe BPI scale defines pain as follows:\n\n1-4 = Mild Pain 5-6 = Moderate Pain 7-10 = Severe Pain\n\nThe total range is 1-10; the higher the score, the higher the pain level.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"1.59"},{"groupId":"OG001","value":"1.71","spread":"1.65"}]}]}]},{"type":"SECONDARY","title":"Average Score on Radiation Therapy Oncology Group (RTOG) Breast Quality of Life Scale","description":"4 levels: 1 = \"Excellent\"; 2 = \"Good\"; 3 = \"Fair\"; 4 = \"Poor.\" The total range is 1-4; the higher the score, the lower the breast quality.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":"0.78"},{"groupId":"OG001","value":"1.96","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"0.78"},{"groupId":"OG001","value":"1.41","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"2.38"},{"groupId":"OG001","value":"2.84","spread":"2.41"}]}]}]},{"type":"SECONDARY","title":"Average Score on Breast Cancer Treatment Outcomes Scale (BCTOS) at the End of Treatment","description":"BCTOS is a validated questionnaire designed to measure breast esthetic and function after breast-conservations treatment. Patients rate the difference between their untreated and treated breast in 3 categories.\n\nThere are 4 score levels: 1 = \"No difference\"; 2 = \"Slight\"; 3 = \"Moderate\"; 4 = \"Large difference\". The total range is 3-12; the lower the score the lower the difference between the untreated and treated breast.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.08","spread":"2.72"},{"groupId":"OG001","value":"7.56","spread":"3.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.29","spread":"3.17"},{"groupId":"OG001","value":"10.10","spread":"3.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.57","spread":"1.34"},{"groupId":"OG001","value":"4.51","spread":"1.51"}]}]}]},{"type":"SECONDARY","title":"Average Score on Breast Cancer Treatment Outcomes Scale (BCTOS)","description":"BCTOS is a validated questionnaire designed to measure breast esthetic and function after breast-conservations treatment. Patients rate the difference between their untreated and treated breast in 3 categories.\n\nThere are 4 score levels: 1 = \"No difference\"; 2 = \"Slight\"; 3 = \"Moderate\"; 4 = \"Large difference\". The total range is 3-12; the lower the score the lower the difference between the untreated and treated breast.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","spread":"3.13"},{"groupId":"OG001","value":"7.01","spread":"2.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.17","spread":"3.07"},{"groupId":"OG001","value":"10.00","spread":"2.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","spread":"1.34"},{"groupId":"OG001","value":"3.80","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Score on \"SF-36 v2 Vitality\" Scale","description":"SF-36 is an extensively used questionnaire designed to compare health status across various populations and is commonly used in cancer trials Our survey includes the portion of the SF-36 focused on the assessment of patient fatigue, or \"vitality,\" at various stages of treatment Example question: How much of the time during the past 4 weeks did you feel full of life? (Answer on scale 1 to 5). 1 = \"All of the time\"; 2 = \"Most of the time\"; 3 = \"Some of the time\"; 4 = \"A little of the time\"; 5 = \"None of the time\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"0.87"},{"groupId":"OG001","value":"3.59","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.32","spread":"0.86"},{"groupId":"OG001","value":"3.25","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Score on \"SF-36 v2 Vitality\" Scale 45-60 Days After Treatment","description":"SF-36 is an extensively used questionnaire designed to compare health status across various populations and is commonly used in cancer trials Our survey includes the portion of the SF-36 focused on the assessment of patient fatigue, or \"vitality,\" at various stages of treatment Example question: How much of the time during the past 4 weeks did you feel full of life? (Answer on scale 1 to 5). 1 = \"All of the time\"; 2 = \"Most of the time\"; 3 = \"Some of the time\"; 4 = \"A little of the time\"; 5 = \"None of the time\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"0.78"},{"groupId":"OG001","value":"2.36","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":"0.92"},{"groupId":"OG001","value":"3.45","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Average Score on Brief Pain Inventory (BPI)","description":"The BPI is a self-administered assessment tool used in pain management.\n\nThe BPI scale defines pain as follows:\n\n1-4 = Mild Pain 5-6 = Moderate Pain 7-10 = Severe Pain\n\nThe total range is 1-10; the higher the score, the higher the pain level.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"1.59"},{"groupId":"OG001","value":"1.66","spread":"1.67"}]}]}]},{"type":"SECONDARY","title":"Average Score on Brief Pain Inventory (BPI)","description":"The BPI is a self-administered assessment tool used in pain management.\n\nThe BPI scale defines pain as follows:\n\n1-4 = Mild Pain 5-6 = Moderate Pain 7-10 = Severe Pain\n\nThe total range is 1-10; the higher the score, the higher the pain level.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"1.51"},{"groupId":"OG001","value":"1.37","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Score on Radiation Therapy Oncology Group (RTOG) Breast Quality of Life Scale, at End of Treatment","description":"4 levels: 1 = \"Excellent\"; 2 = \"Good\"; 3 = \"Fair\"; 4 = \"Poor\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":"0.74"},{"groupId":"OG001","value":"1.95","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.68"},{"groupId":"OG001","value":"1.33","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Score on Radiation Therapy Oncology Group (RTOG) Breast Quality of Life Scale, 45-60 Days After Treatment","description":"4 levels: 1 = \"Excellent\"; 2 = \"Good\"; 3 = \"Fair\"; 4 = \"Poor.\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"0.73"},{"groupId":"OG001","value":"1.94","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"0.72"},{"groupId":"OG001","value":"1.32","spread":"0.67"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":202},"commonTop":["Retraction/Atrophy (Grade 1)","Fibrosis (Grade 1)","Pigmentation Change (Grade 1)","Pain (Grade 1)","Telangiectasia (Grade 1)"]}}}